Multidrug-resistant Acinetobacter baumannii strains with NDM-1: Molecular characterization and in vitro efficacy of
Jingjing Wang1, Yongzhong Ning2, Shu Li3
1Department of Laboratory Medicine, The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471000, P.R. China.
Abstract:
Acinetobacter baumannii is an important cause of hospital-acquired, multidrug-resistant (MDR) infections occurring worldwide. Anti-microbial combination regimens may be the only feasible treatment option for affected patients. In the present study, the efficacy of the combined therapy of meropenem with colistin, ampicillin-sulbactam, tazobactam and vancomycin against clinical strains of MDR A. baumannii was determined. Anti-microbial susceptibility testing was performed and resistance genes were characterized by a multiplex polymerase chain reaction (PCR)-reverse line blot assay. The genetic background of New Delhi metallo-β-lactamase 1 (NDM-1) was analysed by primer walking. The presence of NDM-1 was detected using the modified Hodge test and the EDTA-combined disk test. To screen for synergistic drug effects, the fractional inhibitory concentration index was calculated using a checkerboard assay. The results of the PCR as well as the sequence analyses suggested that NDM-1 was located downstream of the ISAba125 element. In addition, a synergistic effect was determined for meropenem + vancomycin, meropenem + tazobactam and meropenem + ampicillin + sulbactam in two strains each, and in four strains for meropenem + colistin. A total of five A. baumannii strains with resistance to numerous antibiotics and carrying numerous resistance genes were identified. In the strains of A. baumannii, the NDM-1 gene was integrated in a transposon structure with a copy of the ISAba125 insertion sequence. However, the genetic background was not identical among the different species and strains. The genetic variability of NDM-1 may facilitate the rapid dissemination of this gene. In conclusion, meropenem may enhance the efficacy of antibiotics in A. baumannii strains with NDM-1-associated MDR.
Insights
Combination therapies show promise against multidrug-resistant Acinetobacter baumannii. Meropenem combined with vancomycin, tazobactam, ampicillin-sulbactam, or colistin demonstrated synergistic effects, offering new treatment options for NDM-1 positive infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Acinetobacter baumannii is a major cause of hospital-acquired, multidrug-resistant (MDR) infections globally.
- Combination antimicrobial regimens are often the only viable treatment for MDR A. baumannii infections.
- The New Delhi metallo-beta-lactamase 1 (NDM-1) enzyme confers resistance to carbapenems, a critical class of antibiotics.
Purpose of the Study:
- To evaluate the efficacy of meropenem combined with colistin, ampicillin-sulbactam, tazobactam, and vancomycin against clinical MDR A. baumannii strains.
- To characterize antimicrobial resistance genes and the genetic background of NDM-1 in these strains.
- To identify synergistic drug effects in combination therapies.
Main Methods:
- Antimicrobial susceptibility testing was performed.
- Resistance genes were identified using multiplex PCR-reverse line blot assay.
- NDM-1 presence and genetic background were analyzed using primer walking, modified Hodge test, and EDTA-combined disk test.
- Synergistic effects were screened using checkerboard assays to calculate the fractional inhibitory concentration index.
Main Results:
- Five MDR A. baumannii strains carrying multiple resistance genes were identified.
- Synergistic effects were observed for meropenem + vancomycin, meropenem + tazobactam, and meropenem + ampicillin + sulbactam (in two strains each), and meropenem + colistin (in four strains).
- The NDM-1 gene was found integrated in a transposon structure with the ISAba125 insertion sequence, though genetic backgrounds varied.
Conclusions:
- Meropenem-based combination therapies, particularly with colistin, vancomycin, tazobactam, and ampicillin-sulbactam, show synergistic activity against MDR A. baumannii strains.
- The genetic variability of NDM-1, often associated with ISAba125, may contribute to its rapid dissemination.
- Meropenem may enhance the efficacy of other antibiotics in NDM-1-positive MDR A. baumannii infections.
More Related Videos
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
08:58Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
Related Concept Videos
Antimicrobial Effectiveness
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Development of Antibiotic Resistance
